-
1
-
-
33746124186
-
ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes
-
Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120.
-
(2006)
Epilepsia
, vol.47
, pp. 1094-1120
-
-
Glauser, T.1
Ben-Menachem, E.2
Bourgeois, B.3
-
2
-
-
10044228160
-
Therapeutic drug monitoring of old and newer antiepileptic drugs
-
Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer antiepileptic drugs. Clin Chem Lab Med. 2004;42: 1228-1255.
-
(2004)
Clin Chem Lab Med
, vol.42
, pp. 1228-1255
-
-
Neels, H.M.1
Sierens, A.C.2
Naelaerts, K.3
-
3
-
-
33745251005
-
New antiepileptic drugs that are second generation to existing antiepileptic drugs
-
Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006;15:637-647.
-
(2006)
Expert Opin Investig Drugs
, vol.15
, pp. 637-647
-
-
Bialer, M.1
-
4
-
-
34547828792
-
Development of new antiepileptic drugs: Challenges, incentives, and recent advances
-
Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6: 793-804.
-
(2007)
Lancet Neurol
, vol.6
, pp. 793-804
-
-
Perucca, E.1
French, J.2
Bialer, M.3
-
6
-
-
0032420869
-
Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta
-
Myllynen P, Pienimäki P, Raunio H, et al. Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum Exp Toxicol. 1998;17:668-676.
-
(1998)
Hum Exp Toxicol
, vol.17
, pp. 668-676
-
-
Myllynen, P.1
Pienimäki, P.2
Raunio, H.3
-
7
-
-
1842739967
-
Overview of the clinical pharmacokinetics of oxcarbazepine
-
Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Invest. 2004;24:185-203.
-
(2004)
Clin Drug Invest
, vol.24
, pp. 185-203
-
-
Flesch, G.1
-
8
-
-
0030199560
-
Dose-dependent metabolism of carbamazepine in humans
-
Bernus I, Dickinson RG, Hooper WD, et al. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res. 1996;24:163-172.
-
(1996)
Epilepsy Res
, vol.24
, pp. 163-172
-
-
Bernus, I.1
Dickinson, R.G.2
Hooper, W.D.3
-
10
-
-
0026722774
-
A new carbamazepine metabolite in uraemic filtrate
-
Beyer C, Spiteller G. A new carbamazepine metabolite in uraemic filtrate. Xenobiotica. 1992;22:1029-1035.
-
(1992)
Xenobiotica
, vol.22
, pp. 1029-1035
-
-
Beyer, C.1
Spiteller, G.2
-
11
-
-
61849168486
-
Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study
-
Elger C, Halász P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454-463.
-
(2009)
Epilepsia
, vol.50
, pp. 454-463
-
-
Elger, C.1
Halász, P.2
Maia, J.3
-
12
-
-
70349972675
-
Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures
-
Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120:281-287.
-
(2009)
Acta Neurol Scand
, vol.120
, pp. 281-287
-
-
Gil-Nagel, A.1
Lopes-Lima, J.2
Almeida, L.3
-
13
-
-
71949118429
-
Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study
-
Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study. Epilepsia. 2008;49(Suppl 7): 424-425.
-
(2008)
Epilepsia
, vol.49
, Issue.SUPPL. 7
, pp. 424-425
-
-
Ben-Menachem, E.1
Gabbai, A.A.2
Hufnagel, A.3
-
14
-
-
77952746618
-
Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of one-year open-label extension of study BIA-2093-302
-
Gabbai AA, Ben-Menachem E, Maia J, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of one-year open-label extension of study BIA-2093-302. Epilepsia. 2008;49(Suppl 7):432.
-
(2008)
Epilepsia
, vol.49
, Issue.SUPPL. 7
, pp. 432
-
-
Gabbai, A.A.1
Ben-Menachem, E.2
Maia, J.3
-
15
-
-
77951459542
-
Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of one-year open-label extension to study BIA-2093-301
-
Halász P, Elger C, Guekht, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of one-year open-label extension to study BIA-2093-301. Epilepsia. 2008;49(Suppl 7):436.
-
(2008)
Epilepsia
, vol.49
, Issue.SUPPL. 7
, pp. 436
-
-
Halász, P.1
Guekht, E.C.2
-
16
-
-
77955175580
-
Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study
-
Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study. Epilepsia. 2009;50(Suppl 4):71.
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 4
, pp. 71
-
-
Elger, C.1
Halasz, P.2
Maia, J.3
-
17
-
-
77955170803
-
Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study
-
Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study. Epilepsia. 2009;50(Suppl 4):104.
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 4
, pp. 104
-
-
Hufnagel, A.1
Ben-Menachem, E.2
Gabbai, A.A.3
-
18
-
-
77955177172
-
Efficacy and safety of esli-carbazepine acetate as add-on treatment in adults with refractory partial-onset seizures BIA-2093-303 study
-
Lopes-Lima J, Gil-Nagel A, Maia J, et al. Efficacy and safety of esli-carbazepine acetate as add-on treatment in adults with refractory partial-onset seizures BIA-2093-303 study. Epilepsia. 2009;50(Suppl 4):106.
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 4
, pp. 106
-
-
Lopes-Lima, J.1
Gil-Nagel, A.2
Maia, J.3
-
19
-
-
77955175684
-
An investigation of the effect of eslicarbazepine acetate on the pharmacokinetics of carbamazepine: A pooled analysis of three placebo-controlled phase III clinical studies
-
Maia J, Versavel M, Nunes T, et al. An investigation of the effect of eslicarbazepine acetate on the pharmacokinetics of carbamazepine: a pooled analysis of three placebo-controlled phase III clinical studies. Epilepsia. 2009;50(Suppl 11):118-119.
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 11
, pp. 118-119
-
-
Maia, J.1
Versavel, M.2
Nunes, T.3
-
20
-
-
77951455955
-
An investigation of the therapeutic effect of eslicarbazepine acetate combined with carbamazepine: Pooled analysis of three placebo-controlled phase III clinical studies
-
Soares-da-Silva P, Versavel M, Nunes T, et al. An investigation of the therapeutic effect of eslicarbazepine acetate combined with carbamazepine: pooled analysis of three placebo-controlled phase III clinical studies. Epilepsia. 2009;50(Suppl 11):122-123.
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 11
, pp. 122-123
-
-
Soares-Da-Silva, P.1
Versavel, M.2
Nunes, T.3
-
21
-
-
33750366552
-
Pharmacokinetic variability of newer anti-epileptic drugs: When is monitoring needed?
-
Johannessen SI, Tomson T. Pharmacokinetic variability of newer anti-epileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006; 45:1061-1075.
-
(2006)
Clin Pharmacokinet
, vol.45
, pp. 1061-1075
-
-
Johannessen, S.I.1
Tomson, T.2
-
22
-
-
36749058390
-
Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma
-
Alves G, Figueiredo I, Castel-Branco M, et al. Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomed Chromatogr. 2007;21: 1127-1134.
-
(2007)
Biomed Chromatogr
, vol.21
, pp. 1127-1134
-
-
Alves, G.1
Figueiredo, I.2
Castel-Branco, M.3
-
23
-
-
34547193773
-
Stereoselectivity in drug metabolism
-
Lu H. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol. 2007;3:149-158.
-
(2007)
Expert Opin Drug Metab Toxicol
, vol.3
, pp. 149-158
-
-
Lu, H.1
-
24
-
-
0033391871
-
Enantioselective pharmaco-kinetics of 10-hydroxycarbazepine after oral administration of oxcarba-zepine to healthy Chinese subjects
-
Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmaco-kinetics of 10-hydroxycarbazepine after oral administration of oxcarba-zepine to healthy Chinese subjects. Clin Pharmacol Ther. 1999;66: 547-553.
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 547-553
-
-
Volosov, A.1
Xiaodong, S.2
Perucca, E.3
|